Regression Coefficients and Standardized (β) Regression Coefficients From the Fully Adjusted Linear Regression Model Examining the Effects of Baseline FSH on Change in BMD at the Femoral Neck Over the Ensuing 12 Months in 188 Women Diagnosed With Premenopausal Breast Cancer
| . | Coefficient . | β-Coefficient . | SE . | P Value . |
|---|---|---|---|---|
| FSH (IU/L) | −0.0002 | −0.207 | 0.00007 | .02 |
| Age (y) | −0.0003 | −0.056 | 0.0004 | .50 |
| Baseline femoral neck BMD (g/cm2) | −0.0532 | −0.199 | 0.0220 | .02 |
| Treatment group (exercise vs control) | 0.0008 | 0.0145 | 0.0041 | .85 |
| Race/ethnicity (White, Black, Asian, Hispanic) | −0.0005 | −0.021 | 0.0019 | .79 |
| hsCRP (ng/mL) | −0.0000003 | −0.050 | 0.0000005 | .51 |
| Tamoxifen use (yes/no) | 0.0035 | 0.093 | 0.0029 | .23 |
| Menstruating (yes/no) | −0.0016 | −0.022 | 0.0062 | .80 |
| Time from chemotherapy (d) | −0.000007 | −0.039 | 0.00001 | .60 |
| Estradiol (pg/mL) | 0.00001 | 0.031 | 0.00003 | .68 |
| lnCTX (ng/mL) | −0.0029 | −0.058 | 0.0044 | .50 |
| . | Coefficient . | β-Coefficient . | SE . | P Value . |
|---|---|---|---|---|
| FSH (IU/L) | −0.0002 | −0.207 | 0.00007 | .02 |
| Age (y) | −0.0003 | −0.056 | 0.0004 | .50 |
| Baseline femoral neck BMD (g/cm2) | −0.0532 | −0.199 | 0.0220 | .02 |
| Treatment group (exercise vs control) | 0.0008 | 0.0145 | 0.0041 | .85 |
| Race/ethnicity (White, Black, Asian, Hispanic) | −0.0005 | −0.021 | 0.0019 | .79 |
| hsCRP (ng/mL) | −0.0000003 | −0.050 | 0.0000005 | .51 |
| Tamoxifen use (yes/no) | 0.0035 | 0.093 | 0.0029 | .23 |
| Menstruating (yes/no) | −0.0016 | −0.022 | 0.0062 | .80 |
| Time from chemotherapy (d) | −0.000007 | −0.039 | 0.00001 | .60 |
| Estradiol (pg/mL) | 0.00001 | 0.031 | 0.00003 | .68 |
| lnCTX (ng/mL) | −0.0029 | −0.058 | 0.0044 | .50 |
BMD, bone mineral density; hsCRP, high sensitivity C reactive protein; lnCTX, serum C-terminal telopeptide (log transformed); LS, lumbar spine.
Regression Coefficients and Standardized (β) Regression Coefficients From the Fully Adjusted Linear Regression Model Examining the Effects of Baseline FSH on Change in BMD at the Femoral Neck Over the Ensuing 12 Months in 188 Women Diagnosed With Premenopausal Breast Cancer
| . | Coefficient . | β-Coefficient . | SE . | P Value . |
|---|---|---|---|---|
| FSH (IU/L) | −0.0002 | −0.207 | 0.00007 | .02 |
| Age (y) | −0.0003 | −0.056 | 0.0004 | .50 |
| Baseline femoral neck BMD (g/cm2) | −0.0532 | −0.199 | 0.0220 | .02 |
| Treatment group (exercise vs control) | 0.0008 | 0.0145 | 0.0041 | .85 |
| Race/ethnicity (White, Black, Asian, Hispanic) | −0.0005 | −0.021 | 0.0019 | .79 |
| hsCRP (ng/mL) | −0.0000003 | −0.050 | 0.0000005 | .51 |
| Tamoxifen use (yes/no) | 0.0035 | 0.093 | 0.0029 | .23 |
| Menstruating (yes/no) | −0.0016 | −0.022 | 0.0062 | .80 |
| Time from chemotherapy (d) | −0.000007 | −0.039 | 0.00001 | .60 |
| Estradiol (pg/mL) | 0.00001 | 0.031 | 0.00003 | .68 |
| lnCTX (ng/mL) | −0.0029 | −0.058 | 0.0044 | .50 |
| . | Coefficient . | β-Coefficient . | SE . | P Value . |
|---|---|---|---|---|
| FSH (IU/L) | −0.0002 | −0.207 | 0.00007 | .02 |
| Age (y) | −0.0003 | −0.056 | 0.0004 | .50 |
| Baseline femoral neck BMD (g/cm2) | −0.0532 | −0.199 | 0.0220 | .02 |
| Treatment group (exercise vs control) | 0.0008 | 0.0145 | 0.0041 | .85 |
| Race/ethnicity (White, Black, Asian, Hispanic) | −0.0005 | −0.021 | 0.0019 | .79 |
| hsCRP (ng/mL) | −0.0000003 | −0.050 | 0.0000005 | .51 |
| Tamoxifen use (yes/no) | 0.0035 | 0.093 | 0.0029 | .23 |
| Menstruating (yes/no) | −0.0016 | −0.022 | 0.0062 | .80 |
| Time from chemotherapy (d) | −0.000007 | −0.039 | 0.00001 | .60 |
| Estradiol (pg/mL) | 0.00001 | 0.031 | 0.00003 | .68 |
| lnCTX (ng/mL) | −0.0029 | −0.058 | 0.0044 | .50 |
BMD, bone mineral density; hsCRP, high sensitivity C reactive protein; lnCTX, serum C-terminal telopeptide (log transformed); LS, lumbar spine.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
